ABACHEM(300261)2025-01-21 10:56Financial Performance - The company expects a net loss of RMB 185 million to RMB 265 million for the fiscal year 2024, representing an increase in loss of 124.80% to 222.02% compared to the previous year's loss of RMB 82.29 million[3]. - The net loss after deducting non-recurring gains and losses is projected to be RMB 207 million to RMB 287 million, which is an increase of 97.32% to 173.57% compared to last year's loss of RMB 104.91 million[3]. - The decline in performance is attributed to low market conditions in the agricultural chemical sector and significant price drops in core pesticide intermediates, impacting sales negatively[5]. - The company anticipates a substantial goodwill impairment charge due to the impairment testing of goodwill asset groups[6]. Non-Recurring Gains and Losses - Non-recurring gains and losses for 2024 are estimated at approximately RMB 22 million, primarily from fair value changes and government subsidies[6]. Strategic Initiatives - The company is enhancing internal governance and improving information disclosure quality through ESG initiatives, while also focusing on shareholder returns via mid-term dividends[7]. - The agricultural intermediate CDMO business has shown positive development trends following optimization adjustments, with several innovative pesticide products entering various stages of production and certification[7]. - The pharmaceutical business is implementing a multi-dimensional collaborative development strategy, with new facilities in Lanzhou and Shanghai supporting R&D and production synergies[7]. - The company is committed to increasing R&D investment and optimizing existing assets to support innovation in product lines[7]. Forecast and Reporting - The forecasted data is preliminary and subject to change, with final audited financial results to be disclosed in the 2024 annual report[7].